PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
- Conditions
- Non-Alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- Drug: PF-06865571 MonotherapyDrug: PF-05221304 MonotherapyDrug: PlaceboDrug: PF-05221304 and PF-06865571 Combination
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2020-09-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 99
- Registration Number
- NCT03776175
- Locations
- πΊπΈ
Westside Medical Associates of Los Angeles, Beverly Hills, California, United States
πΊπΈProSciento, Inc., Chula Vista, California, United States
πΊπΈCatalina Research Institute, LLC, Montclair, California, United States
Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects
- Conditions
- Healthy Male Subjects
- Interventions
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT03770039
- Locations
- π³π±
PRA Health Sciences, Groningen, Netherlands
π³π±PRA Health Sciences Utrecht, Utrecht, Netherlands
Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.
- Conditions
- Lyme Borreliosis
- Interventions
- Biological: VLA15Biological: Placebo
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 572
- Registration Number
- NCT03769194
- Locations
- πΊπΈ
Stamford Therapeutics Consortium, Stamford, Connecticut, United States
πΊπΈClinical Research Consulting, LLC, Milford, Connecticut, United States
πΊπΈUnited Medical Associates, Binghamton, New York, United States
Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants
- Conditions
- Group B Streptococcus Infections
- Interventions
- Biological: PlaceboBiological: Multivalent Group B streptococcus vaccine
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1208
- Registration Number
- NCT03765073
- Locations
- πΊπΈ
Clinical Research Prime, Idaho Falls, Idaho, United States
πΊπΈVelocity Clinical Research, Cincinnati, Ohio, United States
πΊπΈMedPharmics, LLC, Albuquerque, New Mexico, United States
Clinical Study to Evaluate Blood Concentrations of PF-06700841 After Oral Dose as Different Formulations
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT03765554
- Locations
- π§πͺ
Pfizer Clinical Research Unit, Brussels, Belgium
ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2018-12-04
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03762928
- Locations
- πΊπΈ
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naΓ―ve Adults
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: 20vPnCBiological: 13vPnCOther: SalineBiological: PPSV23
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3902
- Registration Number
- NCT03760146
- Locations
- πΊπΈ
Rapid Medical Research, Inc., Cleveland, Ohio, United States
πΊπΈKaiser Permanente Washington Health Research Institute, Seattle, Washington, United States
πΊπΈHeartland Research Associates, LLC, Wichita, Kansas, United States
A Natural History Study In Chinese Male Patients With Duchenne Muscular Dystrophy
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Other: Visit frequency
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 312
- Registration Number
- NCT03760029
- Locations
- π¨π³
Children's Hospital of Chongqing Medical University (Liangjiang Branch), Chongqing, Chongqing, China
π¨π³Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
π¨π³Huashan Hospital, Fudan University, Shanghai, China
Study To Assess Local Tolerability of Crisaborole 2% Ointment and Vehicle Ointment In Healthy Participants Using Subject-reported Assessments and Objective Measurements
- Conditions
- Healthy
- Interventions
- Drug: Within-Subject Active vs Placebo Topical ApplicationsDrug: Within-Subject Active vs. Placebo Topical Applications
- First Posted Date
- 2018-11-30
- Last Posted Date
- 2019-06-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT03760042
- Locations
- πΊπΈ
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Palatability (Taste) of Oral Formulations of Bosutinib
- Conditions
- CML
- Interventions
- Drug: bosutinib high flavourDrug: Bosutinib MannitolDrug: 200 Mg capsules of bosutinib in Water solutionDrug: bosunitib sorbitolDrug: bosutinib in mannitol low sweetDrug: bosutinib in mannitol high sweetDrug: bosutinib taste low flavourDrug: Bosutinib capsules in low sweetDrug: bosutinib capsules high sweetDrug: bosutinib capsules low flavourDrug: bosutinib capsules in applesauceDrug: Bosutinib capsules in yogurtDrug: bosutinib capsules high flavourDrug: bosutinib capsules in water
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT03747679
- Locations
- π§πͺ
Pfizer Clinical Research Unit, Brussels, Belgium